Key Takeaways
- Price erosion drove a weak quarter: Revenue fell to ₹510 crore (from ₹570 crore YoY) and EBITDA margin compressed 260 bps to 11.4%, as Paracetamol prices cracked >40% and Metformin fell 15-20%.
- Management calls the bottom on API prices: Both ibuprofen and the non-ibuprofen basket (Paracetamol, Metformin) are declared bottomed out, with a northward move expected in 1-2 quarters.
- Non-ibuprofen is the growth engine, but it is stuck: Volumes are rising and capacity utilization hit ~59-60%, yet quarterly revenue has been flat at ~₹95-100 crore for three quarters because price realization collapsed.
- The export pivot is underway but early: Queries and audits are increasing, REACH certification for ethyl acetate is in hand, and the target is to lift export share from ~30% to 45-50% over 3-4 years.
- What to watch next quarter: Whether the called-bottom API prices actually stabilize or tick up, the pace of non-ibuprofen capacity utilization gains, and any signal from the US FDA on the long-pending inspection.
Revenue & Margin Drivers
- Topline hit by price, not volume: Total income dropped ~11% YoY, driven entirely by price erosion in key APIs. Ibuprofen capacity utilization was 80% (vs 85% last quarter) but revenue stayed flat QoQ because prices held and stock was drawn down.
- Raw material timing mismatch: Raw material cost as a percentage of revenue rose both YoY and QoQ. Final product prices fell, but the company was consuming high-cost inventory bought 2-3 quarters earlier, so the margin hit is a lag effect that should unwind if input costs stay benign.
- Other expenses are normalizing: Power and fuel costs, elevated last year by coal prices, have stabilized and declined. Freight costs also came down. Repair and maintenance was higher in prior periods due to boiler expenses and costlier government power; management expects these to sustain at current levels.
- Inventory days rose structurally: Inventory days increased from FY23 to FY24 because new products (Paracetamol, acetic anhydride) expanded the finished-goods pool, and a large alcohol order from one vendor lifted raw material stock.
Mahajan: "The prices are already bottomed out and we are getting regular order at certain prices of ibuprofen. So, we do not fear any more reduction of prices in Ibuprofen."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Pharmaceuticals | ▬ Margin held | EBIT margin maintained at 11.8% as operating expenses eased, despite the revenue decline. |
| Specialty Chemicals | ▲ Inching positive | EBIT margin was only 1% in Q1, but the segment has turned positive at the bottom line over the last 2-3 quarters after earlier losses. Acetic anhydride was launched last year to add value; ethyl acetate received REACH certification. |
| Ibuprofen | ▼ Price pressure | Prices declined from ~$12 four years ago to $9-$10 now. Capacity utilization rose from ~65% in 2022 to 75-85% in FY24, cushioning the revenue impact. |
| Non-ibuprofen APIs | ▲ Volume, ▼ Price | Capacity utilization improved from ~25% two years ago to ~52% last year to ~59-60% now. But revenue is stuck at ~₹95-100 crore per quarter because Paracetamol and Metformin prices collapsed. Paracetamol contribution is now not more than 10-12% of the non-ibuprofen segment after the company intentionally reduced some capacity. |
Non-Ibuprofen Strategy & Capacity Ramp
- The 50% target is intact but delayed: Management still targets non-ibuprofen contributing 50% of API segment turnover in 3-4 years, versus ~20% of overall revenue today. The earlier ₹500 crore target for FY2024 was missed solely because of price falls: at earlier rates, current quantities would have crossed ₹600 crore in FY2024.
- Capacity utilization is the near-term lever: The company expects to ramp capacity utilization to optimum levels within the next 2 years, pending regulatory approvals. All approvals except the US FDA are in hand.
- First priority is consolidation, not expansion: Management explicitly stated the immediate focus is to increase capacity utilization of all existing products and stabilize before considering anything else. New product launches are in the R&D pipeline but not at an announcement stage.
Singh: "If we put those rates at today's quantities, it is going to cross Rs. 600 crore in FY2024. So, we were not knowing that how the prices are going to reduce and prices reduced very substantially for Paracetamol, Metformin and other products also."
Export & Regulatory Pathway
- Export queries are picking up: Clients and competitors with quality issues are coming for audits, and trial orders and samples are being received. Management expects improvement within 3-4 quarters from this pipeline.
- Geographic focus is Europe and Latin America: Most products already have European CEP certification, and expansion will come from European regulated markets and Latin America.
- The US FDA inspection is an open-ended catalyst: The inspection is long overdue, but the US FDA has not informed the company when it will happen (they give only 2-3 days' notice). Management believes the delay reflects the FDA's priorities, not a company-specific issue. When the inspection does occur, most of the 15 filed DMFs may be considered approved at one go.
- Export revenue target: Management aims to lift export share from ~30% to 45-50%, with a loose timeline of 3-4 years.
Singh: "Perhaps this is not their priority. So, that is why they are not inspecting a company like us as of now. But whenever they inspect, most of the filed DMF's for 15 drugs may be considered as US FDA approved at one go."
Competitive Dynamics & SI Group Exit
- SI Group reportedly exiting ibuprofen: Management heard from newspapers that SI Group is planning to exit the ibuprofen business. Per internal sources, SI Group's capacity is ~4,500-5,000 tonnes. If confirmed, this would remove a competitor and could support pricing.
- Management declines to discuss competitor CAPEX: When asked about a competitor ramping up 12,000 tonnes per annum of ibuprofen capacity, management said it does not have a policy to comment on competitors' CAPEX.
- Ibuprofen pricing outlook is cautious: Management believes prices will not go down from present levels, but added that "no one can predict exact numbers" on any upward trajectory.
Capital Allocation & Balance Sheet
- Organic growth first, cash held for opportunities: The first priority is organic growth. Cash is being retained to grab good opportunities in the market if they arise at proper valuations. Management gave a conditional, non-committal answer on whether an acquisition is being planned.
- No buyback, no stock split decision yet: Management's priority is to enhance the business and increase capacities, not a buyback. A bonus or stock split can be discussed in the board, but no decision has been taken. On the stock split, the condition is: let the stock price reach a level where the company can consider it.
- Chemical segment capacity: No immediate plan to expand chemical capacities, though some planning for new launches may come in time.
Singh: "Our priority as of now is to have the business increase at a higher level than considering for buyback."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 13% to 15% | "Near future" |
| API price recovery | Paracetamol and Metformin prices bottomed out, expected to move northward | 1-2 quarters |
| Non-ibuprofen revenue share | 50% of API segment turnover | 3-4 years |
| Capacity utilization | Ramp to optimum level, pending regulatory approvals (all except US FDA) | Within 2 years |
| Export revenue share | Increase from ~30% to 45-50% | 3-4 years |
| Revenue growth | ~10% increase in current year, with >10% from volume and 5-10% from price | Current fiscal year |
| Export query conversion | Improvement from increased queries and audits | 3-4 quarters |
| Other expenses | Power/fuel and repair/maintenance sustained at current levels | Going forward |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Total income | ₹510 cr, vs ₹570 cr in Q1 FY24 and ₹511 cr in Q4 FY24 |
| EBITDA | ₹58 cr, vs ₹80 cr in Q1 FY24 and ₹58 cr in Q4 FY24 |
| EBITDA margin | 11.4%, down 260 bps YoY from 14%, vs 11.3% in Q4 FY24 |
| Net profit | ₹30 cr, vs ₹46 cr in Q1 FY24 and ₹28 cr in Q4 FY24 |
| EBIT margin – Pharmaceutical segment | 11.8% |
| EBIT margin – Specialty Chemical segment | 1% |
| Export revenue | ₹150 cr, vs ₹149 cr in Q1 FY24; 30% of total turnover |
| Revenue growth guidance (FY25) | 10% increase, volume growth more than 10%, price growth 5-10% |
| EBITDA margin guidance (near future) | 13% to 15% |
| Ibuprofen capacity utilization | ~80% |
| Non-ibuprofen capacity utilization | ~59% to 60% on average, minimum 52% product-to-product; up from ~52% last year and ~25% two years back |
| Non-ibuprofen revenue run rate | ~₹95-100 cr per quarter, flattish over last 3 quarters |
| Paracetamol price decline | More than 40% in the last 1 year |
| Metformin price decline | 15% to 20% |
| Net cash | ~₹190 cr as on 30th June 2024 |
| CAPEX target FY25 | ~₹200 cr |
| CAPEX target FY26 | ~₹150 cr |
| Peak revenue potential at current rates | ~₹2,400 to ₹2,500 cr |
| Export revenue target | 45% to 50% of total revenue, in 3-4 years |